Leukemia

On average over 40,000 are diagnosed with leukemia each year in the United States. It is also one of the most common cancers in children. Large differences in therapeutic outcomes exist among patient groups such as children and old age sufferers, and according to the form of a disease that has many variants such as Acute (AML) and Chronic (CML) Myelocytic Leukemia, Acute (ALL) and Chronic (CLL) Lymphocytic Leukemia, and Hairy Cell Leukemia (HCL). These variations have led to unmet needs among specific patient groups. The selection of expert and insightful reports in this section enable you explore these market opportunities by providing key industry data such as drug development strategies, international market trends and forecasts and profiles of major players like Novartis, Pfizer and Bristol-Myers Squibb. Show Less ... more

• 03 - 2012 Emerging Medical Technologies Spotlight: A Report of Investment & Partnering Opportunities

  EURO€ 304.00USD$ 395.00GBP£ 255.00AUD$ 386.00JPY¥ 39,000.00SEK 2 594,00CHF 372.00CAD$ 402.00 Life Science Intelligence, Mar 2012 , Pages: 81
  This report includes details on 61 emerging medical technology companies that have been identified by LSI's in-house research team in March 2012 All companies include technology, market(s), key executive,...

• 02 - 2012 Emerging Medical Technologies Spotlight: A Report of Investment & Partnering Opportunities

  EURO€ 304.00USD$ 395.00GBP£ 255.00AUD$ 386.00JPY¥ 39,000.00SEK 2 594,00CHF 372.00CAD$ 402.00 Life Science Intelligence, Feb 2012 , Pages: 95
  This report includes details on 43 emerging medical technology companies that have been identified by LSI's in-house research team in February 2012 All companies include technology, market(s), key executive,...

• Triple Analysis: Leukemia, Apoptosis and Angiogenesis

  EURO€ 3,450.00USD$ 4,488.00GBP£ 2,903.00AUD$ 4,390.00JPY¥ 443,148.00SEK 29 470,00CHF 4'230.00CAD$ 4,574.00 Bioseeker, Jan 2012 , Pages: 4468
  This triple analysis focuses on cancer drug development strategies in Leukemia and by the two mechanism/target/effect areas of Apoptosis and Angiogenesis. Each of these three individual parts is evaluated...

• Triple Analysis: Colorectal Cancer, Leukemia and Angiogenesis

  EURO€ 3,450.00USD$ 4,488.00GBP£ 2,903.00AUD$ 4,390.00JPY¥ 443,148.00SEK 29 470,00CHF 4'230.00CAD$ 4,574.00 Bioseeker, Jan 2012 , Pages: 3907
  This triple analysis focuses on cancer drug development strategies in both Colorectal Cancer and Leukemia and by the mechanism/target/effect of Angiogenesis. Each of these three individual parts is...

• Triple Analysis: Leukemia, Lung Cancer and Angiogenesis

  EURO€ 3,450.00USD$ 4,488.00GBP£ 2,903.00AUD$ 4,390.00JPY¥ 443,148.00SEK 29 470,00CHF 4'230.00CAD$ 4,574.00 Bioseeker, Jan 2012 , Pages: 4174
  This triple analysis focuses on cancer drug development strategies in both Leukemia and Lung Cancer and by the mechanism/target/effect of Angiogenesis. Each of these three individual parts is evaluated...

• Triple Analysis: Leukemia, Melanoma and Angiogenesis

  EURO€ 3,450.00USD$ 4,488.00GBP£ 2,903.00AUD$ 4,390.00JPY¥ 443,148.00SEK 29 470,00CHF 4'230.00CAD$ 4,574.00 Bioseeker, Jan 2012 , Pages: 3628
  This triple analysis focuses on cancer drug development strategies in both Leukemia and Melanoma and by the mechanism/target/effect of Angiogenesis. Each of these three individual parts is evaluated...

• Triple Analysis: Leukemia, Angiogenesis and Cancer Vaccines

  EURO€ 3,450.00USD$ 4,488.00GBP£ 2,903.00AUD$ 4,390.00JPY¥ 443,148.00SEK 29 470,00CHF 4'230.00CAD$ 4,574.00 Bioseeker, Jan 2012 , Pages: 3510
  This triple analysis focuses on cancer drug development strategies in Leukemia and by the two mechanism/target/effect areas of Angiogenesis and Cancer Vaccines. Each of these three individual parts...

• Global Acute Myeloid Leukemia Drug Pipeline Capsule - 2012

  EURO€ 361.00USD$ 470.00GBP£ 304.00AUD$ 460.00JPY¥ 46,405.00SEK 3 086,00CHF 443.00CAD$ 479.00 Fore Pharma, Jan 2012 , Pages: 15
  Fore Pharma’s latest report ‘Global Acute Myeloid Leukemia Drug Pipeline Capsule – 2012’ is an outline of all the key research and development (R&D) activities of the global Acute Myeloid Leukemia drug...

• Global Chronic Myeloid Leukemia Drug Pipeline Capsule - 2012

  EURO€ 323.00USD$ 420.00GBP£ 272.00AUD$ 411.00JPY¥ 41,468.00SEK 2 758,00CHF 396.00CAD$ 428.00 Fore Pharma, Jan 2012 , Pages: 13
  Fore Pharma’s latest report ‘Global Chronic Myeloid Leukemia Drug Pipeline Capsule – 2012’ is an outline of all the key research and development (R&D) activities of the global chronic myeloid leukemia...

• 01 - 2012 Emerging Medical Technologies Spotlight: A Report of Investment & Partnering Opportunities

  EURO€ 304.00USD$ 395.00GBP£ 255.00AUD$ 386.00JPY¥ 39,000.00SEK 2 594,00CHF 372.00CAD$ 402.00 Life Science Intelligence, Jan 2012 , Pages: 101
  This report includes details on 47 emerging medical technology companies that have been identified by LSI's in-house research team in January 2012 All companies include technology, market(s), key executive,...

• Triple Analysis: Colorectal Cancer, Leukemia and Apoptosis

  EURO€ 3,450.00USD$ 4,488.00GBP£ 2,903.00AUD$ 4,390.00JPY¥ 443,148.00SEK 29 470,00CHF 4'230.00CAD$ 4,574.00 Bioseeker, Dec 2011 , Pages: 3820
  This triple analysis focuses on cancer drug development strategies in both Colorectal Cancer and Leukemia and by the mechanism/target/effect of Apoptosis. Each of these three individual parts is evaluated...

• Triple Analysis: Leukemia, Lung Cancer and Apoptosis

  EURO€ 3,450.00USD$ 4,488.00GBP£ 2,903.00AUD$ 4,390.00JPY¥ 443,148.00SEK 29 470,00CHF 4'230.00CAD$ 4,574.00 Bioseeker, Dec 2011 , Pages: 4087
  This triple analysis focuses on cancer drug development strategies in both Leukemia and Lung Cancer and by the mechanism/target/effect of Apoptosis. Each of these three individual parts is evaluated...

• Triple Analysis: Leukemia, Lymphoma and Apoptosis

  EURO€ 3,450.00USD$ 4,488.00GBP£ 2,903.00AUD$ 4,390.00JPY¥ 443,148.00SEK 29 470,00CHF 4'230.00CAD$ 4,574.00 Bioseeker, Dec 2011 , Pages: 3718
  This triple analysis focuses on cancer drug development strategies in both Leukemia and Lymphoma and by the mechanism/target/effect of Apoptosis. Each of these three individual parts is evaluated according...

• Triple Analysis: Leukemia, Melanoma and Apoptosis

  EURO€ 3,450.00USD$ 4,488.00GBP£ 2,903.00AUD$ 4,390.00JPY¥ 443,148.00SEK 29 470,00CHF 4'230.00CAD$ 4,574.00 Bioseeker, Dec 2011 , Pages: 3541
  This triple analysis focuses on cancer drug development strategies in both Leukemia and Melanoma and by the mechanism/target/effect of Apoptosis. Each of these three individual parts is evaluated according...

• Triple Analysis: Leukemia, Apoptosis and Cancer Vaccines

  EURO€ 3,450.00USD$ 4,488.00GBP£ 2,903.00AUD$ 4,390.00JPY¥ 443,148.00SEK 29 470,00CHF 4'230.00CAD$ 4,574.00 Bioseeker, Dec 2011 , Pages: 3423
  This triple analysis focuses on cancer drug development strategies in Leukemia and by the two mechanism/target/effect areas of Apoptosis and Cancer Vaccines. Each of these three individual parts is...

• Acute Lymphocytic Leukemia (ALL) Therapeutics - Pipeline Assessment and Market Forecasts to 2017

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 GlobalData, Sep 2011 , Pages: 78
  Acute Lymphocytic Leukemia (ALL) Therapeutics - Pipeline Assessment and Market Forecasts to 2017 Summary GlobalData, the industry analysis specialist, has released its new report, “Acute Lymphocytic...

• Chronic Lymphocytic Leukemia (CLL) Global Clinical Trials Review, H2, 2011

  EURO€ 769.00USD$ 1,000.00GBP£ 647.00AUD$ 978.00JPY¥ 98,733.00SEK 6 566,00CHF 943.00CAD$ 1,019.00 GlobalData, Aug 2011 , Pages: 138
  Chronic Lymphocytic Leukemia (CLL) Global Clinical Trials Review, H2, 2011 Summary GlobalData's clinical trial report, “Chronic Lymphocytic Leukemia (CLL) Global Clinical Trials Review, H2, 2011"...

• Chronic Myelocytic Leukemia (CML) Global Clinical Trials Review, H2, 2011

  EURO€ 769.00USD$ 1,000.00GBP£ 647.00AUD$ 978.00JPY¥ 98,733.00SEK 6 566,00CHF 943.00CAD$ 1,019.00 GlobalData, Aug 2011 , Pages: 130
  Chronic Myelocytic Leukemia (CML) Global Clinical Trials Review, H2, 2011 Summary GlobalData's clinical trial report, “Chronic Myelocytic Leukemia (CML) Global Clinical Trials Review, H2, 2011" provides...

• Acute Myelocytic Leukemia (AML) Global Clinical Trials Review, H2, 2011

  EURO€ 769.00USD$ 1,000.00GBP£ 647.00AUD$ 978.00JPY¥ 98,733.00SEK 6 566,00CHF 943.00CAD$ 1,019.00 GlobalData, Aug 2011 , Pages: 116
  Acute Myelocytic Leukemia (AML) Global Clinical Trials Review, H2, 2011 Summary GlobalData's clinical trial report, “Acute Myelocytic Leukemia (AML) Global Clinical Trials Review, H2, 2011" provides...

• Acute Lymphocytic Leukemia (ALL) Global Clinical Trials Review, H2, 2011

  EURO€ 769.00USD$ 1,000.00GBP£ 647.00AUD$ 978.00JPY¥ 98,733.00SEK 6 566,00CHF 943.00CAD$ 1,019.00 GlobalData, Aug 2011 , Pages: 111
  Acute Lymphocytic Leukemia (ALL) Global Clinical Trials Review, H2, 2011 Summary GlobalData's clinical trial report, “Acute Lymphocytic Leukemia (ALL) Global Clinical Trials Review, H2, 2011" provides...

• Global Chronic Myeloid Leukemia Drug Pipeline Capsule - 2011

  EURO€ 284.00USD$ 370.00GBP£ 239.00AUD$ 362.00JPY¥ 36,531.00SEK 2 429,00CHF 349.00CAD$ 377.00 Fore Pharma, Aug 2011 , Pages: 13
  Fore Pharma’s latest report ‘Global Chronic Myeloid Leukemia Drug Pipeline Capsule – 2011’ is an outline of all the key research and development (R&D) activities of the global chronic myeloid leukemia...

• Triple Analysis: Colorectal Cancer, Leukemia and Lung Cancer

  EURO€ 3,450.00USD$ 4,488.00GBP£ 2,903.00AUD$ 4,390.00JPY¥ 443,148.00SEK 29 470,00CHF 4'230.00CAD$ 4,574.00 Bioseeker, Jul 2011 , Pages: 3526
  This triple analysis focuses on cancer drug development strategies in Colorectal Cancer, Leukemia and Lung Cancer. Each of these three individual parts is evaluated according to standardized criteria...

• Triple Analysis: Leukemia, Lung Cancer and Melanoma

  EURO€ 3,450.00USD$ 4,488.00GBP£ 2,903.00AUD$ 4,390.00JPY¥ 443,148.00SEK 29 470,00CHF 4'230.00CAD$ 4,574.00 Bioseeker, Jul 2011 , Pages: 3247
  This triple analysis focuses on cancer drug development strategies in Leukemia, Lung Cancer and Melanoma. Each of these three individual parts is evaluated according to standardized criteria in a five...

• Triple Analysis: Leukemia, Lung Cancer and Cancer Vaccines

  EURO€ 3,450.00USD$ 4,488.00GBP£ 2,903.00AUD$ 4,390.00JPY¥ 443,148.00SEK 29 470,00CHF 4'230.00CAD$ 4,574.00 Bioseeker, Jul 2011 , Pages: 3129
  This triple analysis focuses on cancer drug development strategies in both Leukemia and Lung Cancer and by the mechanism/target/effect of Cancer Vaccines. Each of these three individual parts is evaluated...

• Triple Analysis: Leukemia, Lung Cancer and Lymphoma

  EURO€ 3,450.00USD$ 4,488.00GBP£ 2,903.00AUD$ 4,390.00JPY¥ 443,148.00SEK 29 470,00CHF 4'230.00CAD$ 4,574.00 Bioseeker, Jul 2011 , Pages: 3424
  This triple analysis focuses on cancer drug development strategies in Leukemia, Lung Cancer and Lymphoma. Each of these three individual parts is evaluated according to standardized criteria in a five...

• Chronic Myelogenous Leukemia (CML) Therapeutics - Pipeline Assessment and Market Forecasts to 2017

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 GlobalData, Jun 2011 , Pages: 91
  Chronic Myelogenous Leukemia (CML) Therapeutics - Pipeline Assessment and Market Forecasts to 2017 Summary GlobalData, the industry analysis specialist, has released its new report, “Chronic Myelogenous...

• 2011 Global Markets for External Radiation Therapy

  EURO€ 4,996.00USD$ 6,500.00GBP£ 4,203.00AUD$ 6,357.00JPY¥ 641,764.00SEK 42 678,00CHF 6'126.00CAD$ 6,623.00 Life Science Intelligence, May 2011 , Pages: 129
  2011 Global Markets for External Radiation Therapy is a comprehensive market intelligence solution designed for senior executives who are looking for: - High quality, granular, deeply segmented data...

• 2011 O.U.S. Markets For External Radiation Therapy

  EURO€ 2,998.00USD$ 3,900.00GBP£ 2,522.00AUD$ 3,814.00JPY¥ 385,059.00SEK 25 607,00CHF 3'676.00CAD$ 3,974.00 Life Science Intelligence, May 2011 , Pages: 84
  2011 O U S Markets For External Radiation Therapy is a comprehensive market intelligence solution designed for senior executives who are looking for: - High quality, granular, deeply segmented data...

• 2011 U.S. Markets for External Radiation Therapy

  EURO€ 2,998.00USD$ 3,900.00GBP£ 2,522.00AUD$ 3,814.00JPY¥ 385,059.00SEK 25 607,00CHF 3'676.00CAD$ 3,974.00 Life Science Intelligence, May 2011 , Pages: 66
  2011 U S Markets for External Radiation Therapy is a comprehensive market intelligence solution designed for senior executives who are looking for: - High quality, granular, deeply segmented data -...

• Triple Analysis: Colorectal Cancer, Leukemia and Cancer Vaccines

  EURO€ 3,450.00USD$ 4,488.00GBP£ 2,903.00AUD$ 4,390.00JPY¥ 443,148.00SEK 29 470,00CHF 4'230.00CAD$ 4,574.00 Bioseeker, Apr 2011 , Pages: 2862
  This triple analysis focuses on cancer drug development strategies in both Colorectal Cancer and Leukemia and by the mechanism/target/effect of Cancer Vaccines. Each of these three individual parts...

• Triple Analysis: Leukemia, Melanoma and Cancer Vaccines

  EURO€ 3,450.00USD$ 4,488.00GBP£ 2,903.00AUD$ 4,390.00JPY¥ 443,148.00SEK 29 470,00CHF 4'230.00CAD$ 4,574.00 Bioseeker, Apr 2011 , Pages: 2583
  This triple analysis focuses on cancer drug development strategies in both Leukemia and Melanoma and by the mechanism/target/effect of Cancer Vaccines. Each of these three individual parts is evaluated...

• Triple Analysis: Colorectal Cancer, Leukemia and Melanoma

  EURO€ 3,450.00USD$ 4,488.00GBP£ 2,903.00AUD$ 4,390.00JPY¥ 443,148.00SEK 29 470,00CHF 4'230.00CAD$ 4,574.00 Bioseeker, Apr 2011 , Pages: 2980
  This triple analysis focuses on cancer drug development strategies in Colorectal Cancer, Leukemia and Melanoma. Each of these three individual parts is evaluated according to standardized criteria in...

• A Decision Support Tool for Optimizing The Leukemia Pipeline: From Research and Development to Market

  EURO€ 1,950.00USD$ 2,537.00GBP£ 1,641.00AUD$ 2,481.00JPY¥ 250,475.00SEK 16 657,00CHF 2'391.00CAD$ 2,585.00 Bioseeker, Apr 2011 , Pages: 1147
  This report comprises defined and up to date development strategies for 313 leukemia drugs within the portfolio of 186 companies, from Ceased to Marketed. The report extensively analyses their 204 identified...

• Hairy Cell Leukemia Global Clinical Trials Review, Q1, 2011

  EURO€ 769.00USD$ 1,000.00GBP£ 647.00AUD$ 978.00JPY¥ 98,733.00SEK 6 566,00CHF 943.00CAD$ 1,019.00 GlobalData, Mar 2011 , Pages: 22
  Hairy Cell Leukemia Global Clinical Trials Review, Q1, 2011 Summary GlobalData's clinical trial report, “Hairy Cell Leukemia Global Clinical Trials Review, Q1, 2011" provides data on the Hairy Cell...

• Chronic Lymphocytic Leukemia (CLL) Therapeutics - Pipeline Assessment and Market Forecasts to 2017

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 GlobalData, Mar 2011 , Pages: 80
  Chronic Lymphocytic Leukemia (CLL) Therapeutics - Pipeline Assessment and Market Forecasts to 2017 Summary GlobalData, the industry analysis specialist, has released its new report, “Chronic Lymphocytic...

• Acute Lymphocytic Leukemia - Unmet Needs in Adult and Pediatric Populations Drive Recent Market Developments

  EURO€ 3,536.00USD$ 4,600.00GBP£ 2,975.00AUD$ 4,499.00JPY¥ 454,172.00SEK 30 203,00CHF 4'336.00CAD$ 4,687.00 Decision Resources, Inc, Jun 2010 , Pages: 44
  The heterogeneity of acute lymphocytic leukemia (ALL) makes a universal treatment for the disease extremely difficult to discover and develop: because pediatric and adult ALL are biologically and clinically...

• Chronic Lymphocytic Leukemia: Off-Label Prescribing Drives Market Growth

  EURO€ 3,536.00USD$ 4,600.00GBP£ 2,975.00AUD$ 4,499.00JPY¥ 454,172.00SEK 30 203,00CHF 4'336.00CAD$ 4,687.00 Decision Resources, Inc, Mar 2010 , Pages: 48
  The chronic lymphocytic leukemia (CLL) market is relatively small compared with other cancer markets, yet untapped opportunities exist for companies that can cure the disease or that offer remission-inducing...

• Pipeline Insight: Leukemias Underserved patient populations offer potential for market growth

  EURO€ 8,763.00USD$ 11,400.00GBP£ 7,372.00AUD$ 11,150.00JPY¥ 1,125,556.00SEK 74 851,00CHF 10'745.00CAD$ 11,616.00 Datamonitor, Mar 2010 , Pages: 238
  Introduction Despite major advances in treatment in the last decade, a considerable percentage of the leukemia population still has high unmet needs. Some key oncology companies have entered the leukemias...

• Chronic Myelogenous Leukemia: New Targeted Therapies Take Aim at Gleevec

  EURO€ 1,326.00USD$ 1,725.00GBP£ 1,116.00AUD$ 1,687.00JPY¥ 170,314.00SEK 11 326,00CHF 1'626.00CAD$ 1,758.00 Decision Resources, Inc, Aug 2009 , Pages: 22
  Chronic myelogenous leukemia (CML) is a rare blood cancer; nonetheless, CML treatments garner substantial revenues Despite recent advances in the treatment of this disease (most notably, targeted therapeutics...

• Leukemia - A Competitive Analysis to New Products, Portfolio Planning, Licensing & Acquisition Through Pipeline Benchmarking

  EURO€ 1,950.00USD$ 2,537.00GBP£ 1,641.00AUD$ 2,481.00JPY¥ 250,475.00SEK 16 657,00CHF 2'391.00CAD$ 2,585.00 Bioseeker, Apr 2009 , Pages: 512
  This report includes defined and up to date development strategies for 175 leukemia drugs (>250 projects) within the portfolio of 126 investigators, from Preclinical to Marketed Leukemia drugs are further...

• Leukemia-Analysis to New Products, Portfolio Planning, Licensing & Acquisition Through Pipeline Benchmarking

  EURO€ 1,950.00USD$ 2,537.00GBP£ 1,641.00AUD$ 2,481.00JPY¥ 250,475.00SEK 16 657,00CHF 2'391.00CAD$ 2,585.00 Bioseeker, Apr 2009 , Pages: 512
  This report includes defined and up to date development strategies for 175 leukemia drugs (>250 projects) within the portfolio of 126 investigators, from Preclinical to Marketed Leukemia drugs are further...

• Antibody Drug Targets and Special Focus on Leukemias & Lymphomas

  EURO€ 3,450.00USD$ 4,488.00GBP£ 2,903.00AUD$ 4,390.00JPY¥ 443,148.00SEK 29 470,00CHF 4'230.00CAD$ 4,574.00 Bioseeker, Dec 2007 , Pages: 430
  In this triple analysis report we have analyzed three major and intertwined areas of cancer R&D, Antibody drug target, Leukemias and Lymphomas, which are all subjects to an extensive number of innovative...

• Triple Analysis: Decoding Big Pharma's R&D Strategy in Oncology and Special Focus on Leukemias and Lymphomas

  EURO€ 2,760.00USD$ 3,591.00GBP£ 2,322.00AUD$ 3,512.00JPY¥ 354,518.00SEK 23 576,00CHF 3'384.00CAD$ 3,659.00 Bioseeker, Sep 2007 , Pages: 500
  This is the report for professionals interested to grasp big pharma’s R&D strategy in oncology and at the same time have an extensive R&D overview of the leukemia and lymphoma field This extensive 500+...

• Leukemia - A Therapeutic & Competitive Insight

  EURO€ 1,170.00USD$ 1,522.00GBP£ 984.00AUD$ 1,489.00JPY¥ 150,285.00SEK 9 994,00CHF 1'435.00CAD$ 1,551.00 Bioseeker, Oct 2006 , Pages: 127
  Leukemia includes a broad variety of histological separate disorders which make the leukemia market segmented And even though a high level of unmet medical need, together with its dependence on chemotherapy,...

• Chronic Lymphocytic Leukemia: Monoclonal Antibodies Will Drive Steady Growth

  EURO€ 855.00USD$ 1,112.00GBP£ 719.00AUD$ 1,088.00JPY¥ 109,840.00SEK 7 305,00CHF 1'049.00CAD$ 1,134.00 Decision Resources, Inc, Jun 2006 , Pages: 24
  Chronic lymphocytic leukemia (CLL) is the most common leukemia in the Western world Current research is focusing on the urgent unmet need for agents that improve survival Improved responses from treatment...